Halofantrine (Halfan – SKB) is a new phenanthrene antimalarial introduced last year for the oral treatment of patients with falciparum and vivax malaria. The data sheet states that it is especially useful for the treatment of patients “likely to be infected with chloroquine or multi-drug-resistant strains of malaria”. We have previously discussed drug treatments for choroquine-resistant malaria.1 Where does halofantrine fit in?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.